SEGMENT REPORTING (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Operating Financial Results of Therapeutics Segment

The following table provides the operating financial results of the therapeutics segment:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Revenues:
Product sales, net	$	118,697	$	48,118	$	299,692	$	113,651
License fees and collaboration revenue	—		—		—		2,894
Total revenues	118,697		48,118		299,692		116,545
Operating expenses:
Cost of sales	8,309		3,242		19,757		7,900
Research and development	16,284		12,128		46,287		36,513
Selling and marketing	64,708		35,543		190,851		95,681
General and administrative	43,925		22,367		105,790		72,599
Total operating expenses	133,226		73,280		362,685		212,693
Loss from operations	(14,529)		(25,162)		(62,993)		(96,148)
Other reconciling items(1)	1,944		1,742		4,948		3,707
Net loss	$	(12,585)	$	(23,420)	$	(58,045)	$	(92,441)
Other segment disclosures:
Interest income	$	4,114	$	4,120	$	11,797	$	11,367
Interest expense	$	(2,268)	$	(2,445)	$	(6,721)	$	(5,537)
Depreciation and amortization expense	$	460	$	284	$	1,373	$	793
(1) Other reconciling items primarily includes interest income and interest expense. In the prior year periods, other reconciling items also included loss on debt extinguishment.